Renaissance Capital logo

Tivic Health Systems Priced, Nasdaq: TIVC

Makes a non-invasive neuromodulation device for sinus and nasal inflammation.

Industry: Health Care

Latest Trade: $1.65 0.00 (0.0%)

First Day Return: +3.8%

Return from IPO: -67.0%

Industry: Health Care

Tivic Health Systems, Inc. is a commercial-phase bioelectronic medicine company focused on inflammation. Our first product, ClearUP Sinus Relief (“ClearUP”), is a patented handheld device that uses ultra-low current electrical waves to relieve symptoms of sinus and nasal inflammation. ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances: (US FDA 510(k) number K182025, US FDA De Novo number DEN200006 and EU CE Mark Certificate number CE 704687). ClearUP consistently gets high ratings from consumers across multiple sales platforms. McKinsey & Co estimates that bioelectronic medicine “represents a multibillion dollar opportunity even with modest penetration.” Bioelectronic medicine treats disease and conditions by modulating the electrical signals carried along various nerve pathways. The field grew out of the multi-billion-dollar neuromodulation industry and relied, historically, on implantable devices (e.g. pacemakers, spinal implants, deep brain stimulators). We have shown that ClearUP, a non-invasive bioelectronic therapy, can safely and comfortably deliver therapeutic benefits with a favorable safety profile.
more less
IPO News for Tivic Health Systems
more
IPO Data
IPO File Date 08/03/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 3.0
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/10/2021
Offer Price $5.00
Price Range $5.00 - $6.00
Offer Shares (mm) 3.0
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Newark, CA
Founded 2016
Employees 13
Website www.tivichealth.com